Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates.

ABSTRACT:

Introduction

The pharmacokinetics of vancomycin are highly variable among neonates, which makes dosing challenging in this population. However, adequate drug exposure is critical, especially when treating methicillin-resistant Staphylococcus aureus (MRSA) infections. Utilization of population pharmacokinetic models and Bayesian methods offers the potential for developing individualized therapeutic approaches. To meet this need, a neonatal vancomycin population pharmacokinetic model was recently published. The current study sought to externally evaluate the predictive performance and generalizability of this model.

Methods

A retrospective chart review of neonates who received vancomycin and had ≥1 peak and ≥1 trough concentrations at five Intermountain Healthcare neonatal int

SUBMITTER: Stockmann C 

PROVIDER: S-EPMC4471056 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature